Australia’s innovation powerhouse
The state is an economic powerhouse, boasting Australia’s largest economy, at A$643 billion, and is the 12th largest in the world. More than 600 multinational companies have their regional headquarters in Sydney, and many of Australia’s largest venture capital firms are headquartered here.
NSW has Australia’s largest population, with 8.2 million residents. More than two-thirds of the population hold post-school qualifications. NSW is home to the highest number of STEM graduates in the country and is a top ranked start-up ecosystem in the southern hemisphere.
The NSW public health system is the largest in Australia and one of the best in the world. It benefits from being well connected; world-leading public healthcare is delivered through 228 public hospitals managed by 15 local health districts and two speciality networks, all supported by centralised policy and support pillars.
The state is home to globally significant Health and Innovation Precincts, which provide distinguished crossroads of medicine, science, education, and industry.
A global destination for clinical trials
NSW is at the forefront of global clinical trials activity. Its large and diverse population is complemented by quality research institutions, universities, and a highly networked public health system.
The state’s range of pre-clinical and GMP manufacturing facilities, state-wide public pathology service, world-class biobank, and precision screening platforms provide the infrastructure needed for clinical trial activity in the health system. The NSW Health state-wide biobank accesses the state’s data linkage program. This allows for long-term observation of patient outcomes and access to real-world data.
NSW has a statewide Clinical Trial Support Unit in the Ministry of Health. clinicaltrialsNSW offers Clinical Trial Connect, a free personalised concierge service to assist partners in establishing and conducting clinical trials in the state. Services include logistics support, liaison with clinical trial sites, and introduction to researchers and contract research organisations.
Delivering ground-breaking advanced therapeutics
A research-intensive clinical environment supports NSW’s globally recognised genomics and precision therapeutics researchers.
NSW has specific strengths in:
- regenerative medicine, including gene and cell therapies
- next-generation antimicrobials, including bacteriophage therapy, and
- non-animal alternative technologies, including organoids, bioprinting and AI models.
Broader research priorities include rare diseases, oncology, neuroscience, cardiovascular disease, infectious diseases and medical devices.
NSW has advanced biomanufacturing capabilities that support early-phase research all the way through to GMP manufacturing. The NSW Government has announced significant investments to increase capacity for RNA and viral vector GMP manufacturing. These networked biomanufacturing capabilities support a range of applications including vaccines, infectious disease and gene therapies.
The NSW Government continues to invest in workforce development and collaborative multidisciplinary research networks; and enables infrastructure and health system readiness to fast-track access to the next generation of therapeutics for the state’s population.
Find out more
Visit Investment NSW or contact us at [email protected]
To connect with the NSW Health system contact, [email protected], or visit https://www.medicalresearch.nsw.gov.au/
